NCT01493336View on ClinicalTrials.gov

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Breast Cancer, Colorectal Cancer
Interventions
DRUG

capecitabine RTD

single oral dose

DRUG

capecitabine [Xeloda]

single oral dose

DRUG

capecitabine [Xeloda]

standard treatment

Trial Locations (8)

1010

Grafton

5000

Adelaide

6009

Nedlands

8011

Christchurch

G12 0YN

Glasgow

LS9 7TF

Leeds

WC1E 6AU

London

NE7 7DN

Newcastle upon Tyne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01493336 - A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours | Biotech Hunter | Biotech Hunter